Early HBeAg Loss During Peginterferon alpha-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients

Buster, Erik; Flink, Hajo; ŞİMŞEK, HALİS; Heathcote, E.; Sharmila, Sachithanandan; Kitis, George; Gerken, Guido; Buti, Maria; de Vries, Richard; Verhey, Elke; Hansen, Bettina; Janssen, Harry

doi:10.1038/ajg.2009.371

Early HBeAg Loss During Peginterferon alpha-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients

Atıf İçin Kopyala

Buster E. H. C. J., Flink H. J., ŞİMŞEK H., Heathcote E. J., Sharmila S., Kitis G. E., ...Daha Fazla

AMERICAN JOURNAL OF GASTROENTEROLOGY, cilt.104, sa.10, ss.2449-2457, 2009 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 104 Sayı: 10
Basım Tarihi: 2009
Doi Numarası: 10.1038/ajg.2009.371
Dergi Adı: AMERICAN JOURNAL OF GASTROENTEROLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.2449-2457
Hacettepe Üniversitesi Adresli: Evet

Özet

OBJECTIVES: Treatment with pegylated interferon (PEG-IFN) alpha-2b results in hepatitis B e antigen (HBeAg) loss in 36% of patients at 6 months post treatment. The aim of this study was to determine whether a long-term response to PEG-IFN is dependent on the timing of HBeAg loss.